Poseida Therapeutics, Inc. clinical trials
Acquired by Hoffmann-La Roche, Jan 2025 · source ↗
The registry lists 6 studies whose lead sponsor is Poseida Therapeutics, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 5, 2026.
- 6studies on the registry
- 0open to participants now
Before and after it joined Hoffmann-La Roche
- First submitted before Poseida Therapeutics, Inc. became part of Hoffmann-La Roche
- 6
- First submitted after Poseida Therapeutics, Inc. became part of Hoffmann-La Roche
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
All 6 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 17
- 18
- 19
- 20
- 21
- 222
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Poseida Therapeutics, Inc.6 studies
Something wrong with this grouping? Tell us on the Hoffmann-La Roche page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All Hoffmann-La Roche studies →
- P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid TumorsActive, not recruitingNCT05239143Phase 1
Sponsor listed in the registry: Poseida Therapeutics, Inc. · First submitted before Poseida Therapeutics, Inc. became part of Hoffmann-La Roche
- P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell MalignanciesActive, not recruitingNCT06014762Phase 1
Sponsor listed in the registry: Poseida Therapeutics, Inc. · First submitted before Poseida Therapeutics, Inc. became part of Hoffmann-La Roche
- P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple MyelomaActive, not recruitingNCT04960579Phase 1
Sponsor listed in the registry: Poseida Therapeutics, Inc. · First submitted before Poseida Therapeutics, Inc. became part of Hoffmann-La Roche
- Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101Active, not recruitingNCT03741127Phase 1
Sponsor listed in the registry: Poseida Therapeutics, Inc. · First submitted before Poseida Therapeutics, Inc. became part of Hoffmann-La Roche
- P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)TerminatedNCT04249947Phase 1
Sponsor listed in the registry: Poseida Therapeutics, Inc. · First submitted before Poseida Therapeutics, Inc. became part of Hoffmann-La Roche
- P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)TerminatedNCT03288493Phase 1/2
Sponsor listed in the registry: Poseida Therapeutics, Inc. · First submitted before Poseida Therapeutics, Inc. became part of Hoffmann-La Roche